<DOC>
	<DOCNO>NCT00662025</DOCNO>
	<brief_summary>To evaluate efficacy , safety pharmacokinetics sunitinib plus Capecitabine Japanese patient advanced/metastatic breast cancer .</brief_summary>
	<brief_title>Study Of Sunitinib With Capecitabine In Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologicallyproven diagnosis breast adenocarcinoma amenable surgery , radiation , combine modality therapy curative intent Measurable disease per RECIST . Measurable lesion previously irradiate consider target lesion unless increase size observe follow completion radiation therapy . Prior treatment anthracycline taxane neoadjuvant , adjuvant metastatic disease setting . Histology inflammatory carcinoma measurable disease . Patients histology inflammatory carcinoma allow study measurable disease . Brain metastasis , spinal cord compression , carcinomatous meningitis , leptomeningeal disease . Prior treatment 5fluorouracil ( 5FU ) 5FU derivative Furtulon ( 5'DFUR ) , Futraful/ Sunfural ( tegafur ) , UFT/UFTE ( tegafur/uracil ) , TS1 ( tegafur/gimeracil/oteracil ) Mifurol ( carmofur ) metastatic disease set</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>